Emerging Infectious Disease ISSN: 1080-6059

Worldwide Diversity of Klebsiella pneumoniae That Produce β-Lactamase bla_KPC-2 Gene¹

Gaëlle Cuzon, Thierry Naas

, HaVy Truong, Maria-Virginia Villegas, Karin T. Wisell, Yehuda Carmeli, Ana. C. Gales, Shiri Navon-Venezia, John P. Quinn, and Patrice Nordmann

Author affiliations: Author affiliations: Institut National de la Santé et de la Recherche Médicale, Paris, France (G. Cuzon, T. Naas, H. Truong, P. Nordmann); International Center for Medical Research and Training, Cali, Colombia (M.V. Villegas); Swedish Institute for Infectious Disease Control, Stockholm, Sweden (K.T. Wisell); Sourasky Medical Center, Tel Aviv, Israel (Y. Carmeli, S. Navon-Venezia); Universidade Federal de São Paulo, São Paulo, Brazil (A.C. Gales); John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, USA (J.P. Quinn); Chicago Infectious Disease Research Institute, Chicago (J.P. Quinn)

Main Article

Figure 1

A) Schematic representation of Tn4401 isoforms on plamids of Klebsiella pneumoniae isolates that produce K. pneumoniae carbapenemases (KPCs). Genes and their corresponding transcription orientations are indicated by horizontal arrows. Gray triangles represent the inverted repeats left (IRL) and right (IRR) of Tn4401. Small and empty triangles represent the inverted repeats of ISKpn6 and ISKpn7. Target site duplications (TSD) are indicated above the sequence. Primers listed in Table 2 are shown b

Figure 1. A) Schematic representation of Tn4401 isoforms on plamids of Klebsiella pneumoniae isolates that produce K. pneumoniae carbapenemases (KPCs). Genes and their corresponding transcription orientations are indicated by horizontal arrows. Gray triangles represent the inverted repeats left (IRL) and right (IRR) of Tn4401. Small and empty triangles represent the inverted repeats of ISKpn6 and ISKpn7. Target site duplications (TSD) are indicated above the sequence. Primers listed in Table 2 are shown below, with results of PCRs for each isolate. B) PCR results with primers 7 and 8 (Table 2). Lane 1, K. pneumoniae YC (11); lane 2, K. pneumoniae GR (21); lane 3, K. pneumoniae K271 (25); lane 4, K. pneumoniae KN2303 (13); lane 5, K. pneumoniae KN633 (13); lane 6, K. pneumoniae INC H1521-6; lane 7, K. pneumoniae INC H1516-6; lane 8, K. pneumoniae HPTU 27635; lane 9, K. pneumoniae HPTU 2020532; lane 10, K. pneumoniae A28006 (16); lane 11, K. pneumoniae A28008 (16); lane 12, K. pneumoniae A28009 (16); lane 13, K. pneumoniae A28011 (16); lane 14, K. pneumoniae A33504 (16); lane 15, K. pneumoniae 475; lane 16, K. pneumoniae 588.

Main Article

¹This study was presented in part at the Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12–15; San Francisco, CA, USA.

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.